Gene · 10225
Papers1,736
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 1,736
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| TIGIT contributes to the regulation of 4-1BB and does not define NK cell dysfunction in glioblastoma. | iScience | 2023 | 38053639 | PubTator, text mining | PubMed |
| TREM1 as a novel prognostic biomarker and tumor immune microenvironment evaluator in glioma. | Medicine (Baltimore) | 2023 | 38050264 | PubTator, text mining | PubMed |
| Circulating tumor cells participate in the formation of microvascular invasion and impact on clinical outcomes in hepatocellular carcinoma. | Front Genet | 2023 | 38028589 | PubTator, text mining | PubMed |
| Editorial: A new perspective of human CD8+ T cells with respect to their biology, protective and pathogenic role in anti-viral and tumor responses. | Front Immunol | 2023 | 38022671 | PubTator, text mining | PubMed |
| NK cell exhaustion in the tumor microenvironment. | Front Immunol | 2023 | 38022646 | PubTator, text mining | PubMed |
| Modulation of natural killer cell exhaustion in the lungs: the key components from lung microenvironment and lung tumor microenvironment. | Front Immunol | 2023 | 38022613 | PubTator, text mining | PubMed |
| Identification of necroptosis-related features in diabetic nephropathy and analysis of their immune microenvironent and inflammatory response. | Front Cell Dev Biol | 2023 | 38020922 | PubTator, text mining | PubMed |
| Immune checkpoint inhibitors for multiple myeloma immunotherapy. | Exp Hematol Oncol | 2023 | 38017516 | PubTator, text mining | PubMed |
| Anti-TIM3 chimeric antigen receptor-natural killer cells from engineered induced pluripotent stem cells effectively target acute myeloid leukemia cells. | Cancer Cell Int | 2023 | 38012684 | PubTator, text mining | PubMed |
| Single-cell analysis reveals diversity of tumor-associated macrophages and their interactions with T lymphocytes in glioblastoma. | Sci Rep | 2023 | 38012322 | PubTator, text mining | PubMed |
| Exploiting innate immunity for cancer immunotherapy. | Mol Cancer | 2023 | 38008741 | PubTator, text mining | PubMed |
| CRISPR-Cas9-Based Gene Knockout of Immune Checkpoints in Expanded NK Cells. | Int J Mol Sci | 2023 | 38003255 | PubTator, text mining | PubMed |
| Immunological and senescence biomarker profiles in patients after spontaneous clearance of hepatitis C virus: gender implications for long-term health risk. | Immun Ageing | 2023 | 37978401 | PubTator, text mining | PubMed |
| Silencing of genes by promoter hypermethylation shapes tumor microenvironment and resistance to immunotherapy in clear-cell renal cell carcinomas. | Cell Rep Med | 2023 | 37967556 | PubTator, text mining | PubMed |
| ADSC secretome constrains NK cell activity by attenuating IL-2-mediated JAK-STAT and AKT signaling pathway via upregulation of CIS and DUSP4. | Stem Cell Res Ther | 2023 | 37964351 | PubTator, text mining | PubMed |
| Pan-Cancer Analysis and Experimental Validation of SOX4 as a Potential Diagnosis, Prognosis, and Immunotherapy Biomarker. | Cancers (Basel) | 2023 | 37958409 | PubTator, text mining | PubMed |
| Prognostic Markers within the Tumour Microenvironment in Classical Hodgkin Lymphoma. | Cancers (Basel) | 2023 | 37958391 | PubTator, text mining | PubMed |
| Epigenetic Profiling of PTPN11 Mutant JMML Hematopoietic Stem and Progenitor Cells Reveals an Aberrant Histone Landscape. | Cancers (Basel) | 2023 | 37958378 | PubTator, text mining | PubMed |
| Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma. | J Immunother Cancer | 2023 | 37935564 | PubTator, text mining | PubMed |
Computational identification and clinical validation of a novel risk signature based on coagulation-related lncRNAs for predicting prognosis, immunotherapy response, and chemosensitivity in colorectal cancer patients. | Front Immunol | 2023 | 37928532 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10225/papers?page=9